Pliant Therapeutics (PLRX) Statistics

Over the past year, Pliant Therapeutics (PLRX) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 18.98%, Pliant Therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 31.71%, it has fallen short of the market average. This comparison highlights Pliant Therapeutics 's performance relative to both its sector and the overall market over the last year.

The PE ratio for Pliant Therapeutics (PLRX) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.

The Earnings Per Share (EPS) for Pliant Therapeutics (PLRX), calculated on a diluted basis, is -$3.35. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.

The operating margin for Pliant Therapeutics (PLRX) is 0%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Pliant Therapeutics (PLRX) is -$219.95M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

Pliant Therapeutics (PLRX) has a total debt of $60.21M. The net debt, which accounts for cash and cash equivalents against the total debt, is -$19.4M.